Mobius Scientific develops therapeutic platforms that target the underlying mechanisms of age‑related macular degeneration and other retinal diseases. By delivering gene‑based or cell‑based treatments to the retina, the company aims to halt or reverse progressive vision loss for patients. Revenue is generated through product sales and licensing agreements with pharmaceutical partners once its therapies reach market approval.
Funding
Funding not disclosed
Founders
Product
Problem
Over 200 million individuals annually experience vision loss due to age-related macular degeneration, a condition often considered an inevitable and unpreventable consequence of aging. This progressive vision impairment significantly impacts quality of life.
Solution
Mobius Scientific is developing novel therapeutic agents targeting the underlying pathology of retinal diseases, specifically age-related macular degeneration. Their platform leverages proprietary technology to address the root causes of vision loss, aiming to restore or preserve visual function. By focusing on these fundamental disease mechanisms, Mobius Scientific seeks to establish a new standard of care for patients suffering from progressive vision impairment.
Target Audience
The primary target audience includes patients with age-related macular degeneration and other progressive retinal diseases, as well as ophthalmologists and researchers in the field of vision science.
Features
- Development of novel therapeutic candidates for retinal diseases.
- Focus on addressing the root causes of vision loss.
- Platform technology designed for broad application in ophthalmology.